

**Curriculum Vitae  
Walter K. Kraft**

November 25, 2021

**Office Address:**

Clinical Pharmacology	Office of Human Research
1170 Main Building, 132 South 10th St. Philadelphia, PA 19107	M-34 Jefferson Alumni Hall 1015 Walnut, St. Philadelphia, PA 19107

[walter.kraft@jefferson.edu](mailto:walter.kraft@jefferson.edu)

**Education:**

1986-90      BA      The American University  
1991-95      MD      University of Pittsburgh  
2001-06      MS      Thomas Jefferson University (Pharmacology)

**Postgraduate Training and Fellowship Appointments:**

1995-96      Intern in Medicine, Thomas Jefferson University Hospital  
1996-98      Resident in Medicine, Thomas Jefferson University Hospital  
1998-99      Chief Medical Resident, Thomas Jefferson University Hospital,  
1999-01      Research Fellow in Clinical Pharmacology, Thomas Jefferson University

**Uniformed Service:**

1993              Ensign, U.S. Public Health Service, Junior Commissioned Officer Student  
Training and Extern Program, Dover, Delaware (2 month service in migrant  
health clinic)

**Faculty Appointments:**

Thomas Jefferson University, Philadelphia, PA  
2014              Professor (tenure-track) of Pharmacology and Experimental Therapeutics,  
Department of Pharmacology and Experimental Therapeutics  
2014              Professor of Medicine, Department of Medicine (secondary appointment)  
2014              Professor of Surgery, Department of Surgery (secondary appointment)  
2011-2014      Associate Professor of Surgery  
2008-2014      Associate Professor of Pharmacology and Experimental Therapeutics  
2008-2014      Associate Professor of Medicine  
2008-              Faculty of the Jefferson College of Life Sciences  
2005-2008      Assistant Professor of Pharmacology and Experimental Therapeutics,  
2001-2008      Assistant Professor of Medicine

**Administrative Appointments:**

Clinical Research Unit, Thomas Jefferson University  
2001-06              Associate Medical Director  
2006-                  Director  
Division of Clinical Pharmacology, Department of Pharmacology and Experimental  
Therapeutics  
2006-                  Director,  
Office of Human Research, Thomas Jefferson University  
2012-15              Associate Director  
2015-                  Director

**Hospital Appointments**

1999-03              Staff Physician and Admitting Officer, VA Medical Center, Wilmington, DE  
2001-05              Medical Consulting Staff, Wills Eye Hospital, Philadelphia, PA  
2001-                  Admitting Staff, Thomas Jefferson University Hospital, Philadelphia, PA

2005-08 Medical Consulting Staff, Jefferson Hospital for Neuroscience, Philadelphia, PA  
2009-10 Interim Director, Antithrombotic Service, Thomas Jefferson University Hospital  
2010- Attending, Jefferson Vascular Center  
2010- Admitting Staff, Methodist Hospital, Philadelphia, PA

**Specialty Certification:**

American Board of Internal Medicine  
1998-2022 Continuously Certified

American Board of Clinical Pharmacology  
2003 Certification

**Licensure:**

Pennsylvania

**Awards, Honors and Membership in Honorary Societies:**

2006- Fellow, American College of Physicians  
2007-2019 United States Pharmacopeia, Thomas Jefferson University Representative  
2007 Member of the Month, December 2007, American Society for Clinical  
Pharmacology and Therapeutics (ASCPT)  
2008 Golden Apple Teaching Award, Thomas Jefferson University Hospital Internal  
Medicine Residency  
2008 Top 25 Most Highly Rated Teachers, Thomas Jefferson University Hospital  
Internal Medicine Residency  
2009 Dedicated Member, October 2009, ASCPT  
2010 Jefferson Medical College Early Career Investigator Award for Distinguished  
Achievement in Biomedical Research  
2014 Dean's Award for Excellence in Education, Jefferson Medical College  
2020 Faculty Team Achievement Award, Sidney Kimmel Medical College  
2022 Henry W. Elliott Distinguished Service Award, ASCPT

**NIH & PCORI Committee Service**

2007-08 NIH Special Emphasis Panel/Scientific Review Group 2007 and 2008 ZGM1  
BRT-5 (PG) T32 Mechanism  
2010 NIH/NICHD ZHD1 DSR-A: K23 Review Committee  
2010 NIH/NICHD ZHD1 DSR-K: Pediatric Clinical Trials Network Review Committee  
2010 NIH ZRG1 Special Emphasis Panel EMNR-P (50) R: RFA Panel: Translational  
Research in Pediatric and Obstetric Pharmacology  
2011 NIH/NICHD ZRG1 EMNR-K (55) R RFA Panel: Translational Research in  
Pediatric and Obstetric Pharmacology  
2011 Special Emphasis Panel/ SRG 2011/08 ZHD1 DSR-A (50) 2  
2012 NIDA Multisite Medications Development for SUD, ZDA1 GXM-A (08)  
2014 NIH/NICHD PAR 13-309/310/311: Translational Research in Pediatric and  
Obstetric Pharmacology  
2014 ZHL1 CSR-G (S1), NIH Special Emphasis Panel: RFA HL-14-019: Low-Cost,  
Pragmatic, Patient-Centered Randomized Controlled Intervention Trials  
(UH2/UH3) and the RFA-HL-14-020: Evaluation and Administration Coordinating  
Center  
2014-16 Xenobiotic and Nutrient Disposition and Action (XNDA) Study Section ad hoc  
member  
2015 Special Emphasis Panel: PAR13-309-311: Translational Research in Pediatric  
and Obstetric Pharmacology and Therapeutics, ZRG1 EMNR-D (55)  
2015 Special Emphasis Panel: PAR13-309-311: Translational Research in Pediatric  
and Obstetric Pharmacology and Therapeutics ZRG1 EMNR-W (55)  
2016 SBIR contract review, NIDA Topic 158, N43DA-16-1210, "Development of Primer  
and Reference Tool to Assess Neonatal Abstinence Syndrome."

2017 Special Emphasis Panel ZRG1 EMNR-S 55: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics  
 2018 PO1 PAR-16-393 Review, NIDA  
 2019 NCATS Therapeutic Development Branch; reviewer, Pre-Clinical Drug Development program  
 2019 NICDH RFA HD-19-025 review  
 2019 NICHD ZHD1 DSR-Z(50)  
 2020 NCCIH ZAT1 SM (54) Early Phase Clinical Trials of Natural Products  
 2020 Special Emphasis Panel ZRG1 EMNR-S 55: Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics  
 2021 PCORI Phased Large Awards for Comparative Effectiveness Research Phase III, Reviewer  
 2021 2021/10 ZTR1 CI-4 (01) 1: CTSA Collaborative Innovation Award (U01/R21) Special Emphasis Panel  
 2021 Developmental Brain Disorders study section ad hoc reviewer  
 2021 PCORI clinical trial report peer reviewer

**FDA Service**

Pharmaceutical Science and Clinical Pharmacology Advisory Committee

2018-2022 Member  
 2021-2022 Chair

2018 Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory Committee. Senseonics Eversense Continuous Glucose Monitoring System, March 29, 2018

2019 Clinical Pharmacology Advisory Committee Meeting, Renal Drug Development, May 7, 2019

Endocrinologic and Metabolic Drugs Advisory Committee, November 14, 2019

2021 Arthritis Advisory Committee, Avacopan for ANCA vasculitis, May 6, 2021

**State Department Service**

2014-16 Faculty Expert, Guideline generation for treatment of drug abuse in children under 12 years

**Pennsylvania Perinatal Quality Collaborative**

2019 Work group member

**FDA Investigational New Drug Approval (IND) Grantees as Sponsor**

# 68,403 Buprenorphine in the Treatment of the Neonatal Abstinence Syndrome  
 # 75,012 Capsaicin Inhalation for Induction of Cough (inactive)  
 #116,387 Exploration of Early Renal Injury Biomarkers Using Tenofovir Disoproxil Fumarate (inactive)  
 # 123,173 Apixaban Anticoagulation Reversal Using KCENTRA (Human 4 Factor Prothrombin Complex Concentrate) (inactive)  
 #143,072 Effect of Once-Weekly Rifapentine and Isoniazid on the Pharmacokinetics of Steady-State Doravirine

**Memberships in Professional and Scientific Societies:**

American College of Clinical Pharmacology (2003-2019)  
 American College of Physicians  
     1997-06      Member  
     2006-         Fellow  
 American Society for Clinical Pharmacology and Therapeutics (2001- )  
 Association of Clinical Pharmacology Units (2010-14)  
 Association for Clinical Research Training (2006-08)

**National Professional and Scientific Committee Leadership**

American Society for Clinical Pharmacology and Therapeutics  
     2006-09      Scientific Program Committee  
     2009-19      Finance Committee  
     2014-15             Vice Chair  
     2014-19      Board of Directors  
     2016-19      Treasurer  
     2020         Strategic Plan Tactical Task Force

American College of Clinical Pharmacology  
     2014         Co-chair, Program Committee, Scientific Meeting  
     2015         Member, Program Committee, Scientific Meeting

American Board of Clinical Pharmacology  
     2007-12      Governing Board Member,  
                   -Chair By-Laws Committee  
                   -Member, Executive Committee

United States Pharmacopeia  
     2007-19      Medical School Representative

Association of Clinical Pharmacology Units  
     2010-12      Board of Directors  
     2013         Annual Meeting Program Chair

National Board of Medical Examiners  
     2009         Member, Standards Setting Panel for USLME Step 1

Critical Path Initiative  
     2015         Member, INC Clinical Pharmacology Workgroup

**Ad Hoc Reviewer:**

Advances in Therapy	Clinical Pharmacology and Therapeutics
American Journal of Obstetrics & Gynecology	Clinical Pharmacology in Drug Development
Maternal Fetal Medicine	Contemporary Clinical Trials
American Journal of Perinatology	Current Pharmaceutical Design
<a href="#">Annals of Internal Medicine</a>	Drug and Alcohol Dependence
Archives of Disease in Childhood,	European Journal of Drug Metabolism and
Biology of Blood and Marrow Transplantation	Pharmacokinetics
BMC Clinical Pharmacology	Expert Opinion on Drug Metabolism and
BMC Pediatrics	Toxicology
British Journal of Clinical Pharmacology	Expert Opinion on Pharmacotherapy
Canadian Medical Association Journal	Frontiers Pediatrics
Children	Human Psychopharmacology
Clinical and Experimental Gastroenterology.	Nature Reviews Disease Primers
<a href="#">Clinical and Translational Science</a>	Neuropsychopharmacology
Clinical Pharmacokinetics	New England Journal of Medicine

Journal of Addiction Medicine  
 Journal of the American Osteopathic Association  
 Journal of Clinical Pharmacology  
 Journal of Developmental Origins of Health and Disease  
 Journal of Neonatal-Perinatal Medicine  
 Journal of Pediatrics  
 Journal of Perinatology  
 Journal of Pharmacy and Pharmacology  
 Journal of Thrombosis and Haemostasis

Journal of Maternal-Fetal & Neonatal Medicine  
 Neuropsychopharmacology  
 Pediatrics  
 Pharmacogenomics  
 Pharmacotherapy  
 Preventative Medicine  
 Substance Abuse: Research & Treatment  
 The Pharmacogenomics Journal  
 Therapeutics and Clinical Risk Management  
 Therapeutic Delivery

**Editorial Positions:**

2002-06 Editorial Review Board, Journal of Applied Research  
 2006-08 Associate Editor, Waldman SA, Terzic A, Eds., Pharmacology and Therapeutics: Principles to Practice, 1st. Ed., Saunders Elsevier; 2008  
 2013-15 Associate Editor, [Current Therapeutic Research](#)  
 2018-20 Editorial Board, [Clinical and Translational Science](#)  
 2020- Associate Editor, [Clinical Pharmacology and Therapeutics](#)  
 2021- Editorial Board Member, [Children](#)

**Academic Committees at the Thomas Jefferson University/ Sidney Kimmel Medical College and Affiliated Hospitals:**

*Present Committee Membership*

Institutional Review Board

1999- Full board member  
 2003-10 Serious adverse event reviewer  
 2006 Association for Accreditation of Human Research Protection Programs Advisory Committee  
 2007 Ad hoc SOP reviewer, Leadership Council of Clinical Coordinators  
 2008-15 Vice Chair, Weinstein Committee  
 2010- Gene Transfer Review Committee  
 2013-15 Associate Director, Office of Human Research  
 2015- Director, Office of Human Research

Department of Pharmacology and Experimental Therapeutics

2006- Promotion Committee

Sidney Kimmel Medical College (current)

Scholarly Inquiry (formerly College within a College), Clinical and Translational Science Track  
 2010-15 Founding Director  
 2015-16 Co-Director  
 2017- Associate Director  
 2017- Clinical Research Leadership Council  
 2019-2023 Clinical representative on the SKMC Executive Committee

Thomas Jefferson University Hospital

2011- Pharmacy and Therapeutics subcommittee, Cardiology/Thrombosis

*Past Committee Membership*

Thomas Jefferson University and Hospital

1999-2010 Curriculum Committee  
 2001-10 Internal Medicine Residency Competency Committee (Member)  
 2007-10 Competency Committee (Chair)

2001-02	Educational Task Force, Department of Medicine
2001-03	Jefferson University Physicians Advisory Board
2008	4 <sup>th</sup> Year Advanced Basic Science Curriculum Working Group
2008	Committee on Student Affairs
2010	Fourth Year Elective Working Group
2008-10	Thomas Jefferson University Intellectual Property Policy Committee
2010-11	Search Committee Member, Chairperson of Department of Obstetrics and Gynecology
2010-14	Pharmacy and Therapeutics subcommittee, Medication Events and Drug Safety
2010-14	Living Donor Organ Transplant Independent Advocate
2011	Internal Review Committee, Department of Emergency Medicine Residency Program
2011	Internal Review Committee, Department of Family and Community Medicine
2011-12	Critical Thinking Task Force
2011-12	Faculty Research Awards Task Force
2011-15	Committee on Research Internal Awards Subcommittee Student Awards Subcommittee Chair
2011-17	Curriculum Committee
2012	Dean's Advisory Council on Research
2013	Internal Review Committee, Department of Ophthalmology
2014	Internal Review Committee, Department of Neurosurgery
2013-14	Admissions Day Keynote Speaker
2013-14	LCME Taskforce on Faculty
2014-2019	SKMC Council for Diversity and Inclusion
2014-2020	Student Research Awards Director
2014	Clinical Research Planning Oversight Committee Team Leader, Program, Service and Regulatory Model
2015	Search Committee, Associate Dean for UME/AA
2015-16	CME Committee
2015-16	JeffMD Curriculum Redesign Steering Committee Scholarly Activity Subcommittee Chair
2015-17	Jefferson Clinical Research Institute Advisory Board Member
2015-17	EPIC Implementation Team, Co-Chair of the Academic Advisory Committee
2017	Internal Review Committee, Department of Medicine
2018-19	Opioid Taskforce, Policy Subcommittee
2007-20	Kimmel Cancer Center Data and Safety Monitoring Board
2019-20	Internal Review Committee, Department of Medical Oncology
2018-20	Enterprise-wide Pharmacy and Therapeutics Council

**Major Teaching and Clinical Responsibilities at the Thomas Jefferson University and Affiliated Hospitals:**

*Educational Leadership (at Thomas Jefferson University)*

2001-02	Educational Task Force, Department of Medicine
2001-	House staff rotation coordinator, Department of Pharmacology and Experimental Therapeutics
2004-10	Associate Director, K30 Program in Human Investigation
2005	Faculty Development Program presentation, "Evidence-based bedside teaching"
2006-	Associate Program Director, Clinical Pharmacology Fellowship program
2006-	Coordinator, "Seminars in Human Investigation", Department of Pharmacology and Experimental Therapeutics
2007-12	Section leader (Medical Reading) for 4 <sup>th</sup> year JMC elective, Scientific Foundations of Clinical Medicine
2007-	Coordinator, "Gruber Lecture", Endowed lectureship in Pharmacology
2007-14	Course Director, Pharm 401, Principals of Clinical Pharmacology/Advanced Basic Science
2008	4 <sup>th</sup> Year Advanced Basic Science Curriculum Working Group

2010 College within a College, Clinical and Translational Subcommittee  
 2010 Fourth Year Elective Working Group  
 2010-16 Director, College within a College, Clinical and Translational Science  
 2011- Director, K30 Program in Human Investigation  
 2012 Coordinator, Summer Student Research Seminars  
 2015- Course Director, PR 525, Clinical Pharmacology  
 2015-20 Course Co-Director, CG 960, Regulatory Issues In Scientific Affairs

**Educational Activities**

	<b>Course #</b>		<b>Direct Lecture hours</b>	<b>Students</b>
<b>College of Graduate Studies</b>				
1999-03	PR 760	Case Studies in Clinical Pharmacology	5	6
1999-12 2015-20	PR 522	General Pharmacology	4	30
2000-21	PR 525	Clinical Pharmacology*	6	20
2001-14	GC 630	Fundamentals of Clinical Trials	10	20
2017	GC 640	Research Ethics	1	30
2002-19	CG 690	Regulatory Issues In Scientific Affairs*	4	16
2016	LS 603	Research Design	1	30
<b>Sidney Kimmel Medical College</b>				
1997-99		Physical Diagnosis (2 <sup>nd</sup> year)	10	5
2001-06		Ward Attending, General Medical Service, TJUH		3
2001-03		Practical History and Physical examinations (3 <sup>rd</sup> year)	15	1
2000-14	PR 401	Clinical Pharmacology*	10	70
2001-18	PR 200	Foundations of Clinical Medicine	6	250
2007-18		Foundations of Clinical Pharmacology	3	250
2002-08		Residency Core Curriculum Lectures	3	30
2008-10		Residency Journal Club Facilitator	6	30
2002-21		Jefferson Antithrombotic Service Consult Attending, TJUH		1
2003-14		Scientific Foundations of Clinical Medicine Journal Review (4 <sup>th</sup> year)	10	70
2012-17		Summer research student seminar	2	50
2018-		JeffMD Core Pharmacology lectures	6	260
2020-	JMD 467	Clinical Pharmacology Advanced Basic Science*	8	40

\*Course Director or co-director

**Bibliography**

**Publications, peer reviewed:**

1. Kraft W, Greenberg H, Waldman S. Paradoxical Hypotension and Bradycardia after Intravenous Arginine Vasopressin. Journal of Clinical Pharmacology. 1998; 38:283-286 [PMID 11522118]
2. Kraft WK, Waldman SA. Manufacturer's drug interaction and post-market adverse event data: What are appropriate uses? Drug Safety. 2001; 24:637-643 [PMID 11522118]
3. Hastie AT, Kraft WK, Nyce KE, Zangrilli JG, Fish JP, Peters SP. Kinetics of Airway Epithelial Cell Proliferation And Stimulation of Collagen After Segmental Allergen Challenge. American Journal of Respiratory and Critical Care Medicine. 2002; 165:266-272 [PMID 11790666]  
<http://ajrccm.atsjournals.org/content/165/2/266.long>

4. Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, VanBuren S, Waldman SA, Greenberg HE. Effects of Aprepitant on the Pharmacokinetics of Ondansetron and Granisetron in Healthy Subjects. *Clinical Therapeutics*. 2003; 25:1407-19 [PMID 12867217]
5. Burke J, Kraft WK, Greenberg HE, Gleave M, Pitari GM, VanBuren S, Wagner J, Waldman SA. Relationship of Arachidonic Acid Concentration to Cyclooxygenase-Dependent Human Platelet Aggregation. *Journal of Clinical Pharmacology*. 2003; 43:983-989 [PMID 12971030]
6. Kraft WK, Steiger B, Beussink D, Quiring JN, Fitzgerald N, Greenberg HE, Waldman SA. The Pharmacokinetics of Nebulized Nanocrystal Budesonide Suspension in Healthy Volunteers. *Journal of Clinical Pharmacology*. 2004; 44:67-72 [PMID 14681343]
7. Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and Rifabutin Drug Interactions in Healthy Volunteers. *Journal of Clinical Pharmacology*. 2004; 44:305-13 [PMID 14973305]
8. Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. The Effects of Modifying In-Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity. *Journal of Clinical Pharmacology*. 2004, 44:1125-1131 [PMID 15342613]
9. Stone JA, Migoya EM, Hickey L, Winchell GA, Deutsch PJ, Ghosh K, Freeman A, Bi S, Desai R, Dilzer SC, Lassetter KC, Kraft WK, Greenberg HE, Waldman SA. Potential for Drug Interactions between Caspofungin and Nelfinavir or Rifampin. *Antimicrobial Agents and Chemotherapy*. 2004; 48(11):4306-14 [PMID 15504857]
10. Filicko J, Kakhniashvili I, Kraft WK, Flomenberg N. Heterogeneous Clearance of Anti-Thymocyte Globulin (ATG) Following CD34+ Selected Allogeneic Hematopoietic Progenitor Cell Transplantation (HPCT). *Biology of Blood and Bone Marrow Transplantation*. 2005, 11(8):609-18 [PMID 16041311]
11. Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF. Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects. *Journal of Clinical Pharmacology*. 2006;46:321-327 [PMID 16490808]
12. Patel T, Pequignot E, Parker SH, Leavit MC, Greenberg HE, Kraft WK. Transgenic Avian Derived Glycosylated Recombinant Human Interferon Alpha-2b (AVI-005): An Open Label, Controlled, Single Dose Study in Healthy Subjects. *International Journal of Clinical Pharmacology and Therapeutics*. 2007;45(3):161-68 [PMID 17416111] <http://jdc.jefferson.edu/petfp/29/>
13. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The Pharmacokinetics of Taurolidine Metabolites in Healthy Volunteers. *Journal of Clinical Pharmacology*. 2007;47:697-703 [PMID 17395893] <http://jdc.jefferson.edu/petfp/26/>
14. Majumdar AK, Yan KX, Selverian DV, Barlas S, Constanzer M, Dru J, McCrea JB, Ahmed T, Frick GS, Kraft WK, Petty KJ, Greenberg HE. Effect of Aprepitant on the Pharmacokinetics of IV Midazolam. *Journal of Clinical Pharmacology*. 2007;47:744-750 [PMID 17463213]
15. Ghanim AJ, Daskalakis C, Eschelmann EJ, Kraft WK. A Five-Year Retrospective, Comparison Review of Survival in Neurosurgical Patients Diagnosed with Venous Thromboembolism and Treated with Either Inferior Vena Cava Filters or Anticoagulants. *Journal of Thrombosis and Thrombolysis*. 2007; 24(3):247-54 [PMID 17385008]

16. Kraft WK, Gibson E, Dysart K, Damle V, LaRusso J, Greenspan J, Moody D, Kaltenbach K, Ehrlich M. Sublingual Buprenorphine for Treatment of the Neonatal Abstinence Syndrome: A Randomized Trial. *Pediatrics*. 2008; 122:e601-7 [PMID 18694901]  
<http://pediatrics.aappublications.org/content/122/3/e601.long>
17. Varki R, Pequignot E, Leavitt MC, Ferber A, Kraft WK. A Glycosylated Recombinant Human Granulocyte Colony Stimulating Factor Produced in a Novel Protein Production System (AVI-014) in Healthy Subjects: A First-in Human, Single Dose, Controlled Study. *BMC Clinical Pharmacology* 2009, 9(1):2 [PMID 19175929]  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2639539/?tool=pubmed>
18. Loboda A\*, Kraft WK\*, Joseph J, Fine B, Nebozhyn M, Zhang C, He Y, Yang X, Wright C, Morris M, Chalikonda I, Ferguson M, Dai H, Emilsson V, Schadt E, Greenberg HE, Lum PY. Diurnal variation in human adipose and its link to metabolic diseases and mTOR signaling. *BMC Medical Genomics* 2009, 2:7 [PMID 19203388] \*contributed equally to this manuscript  
<http://www.biomedcentral.com/1755-8794/2/7>
19. Kim DH, Daskalakis C, Whellan DJ, Whitman IR, Hohmann S, Medvedev S, Kraft WK. Safety of Selective Serotonin Reuptake Inhibitor in Adults Undergoing Coronary Artery Bypass Grafting. *American Journal of Cardiology*. 2009; 103:1391-5 [PMID 19427434]
20. Lai E, Schwartz JI, Dallob A, Jumes P, Liu F, Kraft WK, Royalty J, Chodakewitz J, Sisk CM, Radziszewski W, Wagner JA. Effects of Extended Release Niacin/Laropiprant, Laropiprant, Extended Release Niacin, and Placebo on Platelet Aggregation and Bleeding Time in Healthy Subjects. *Platelets*. 2010; 21(3):191-8 [PMID: 20163197]
21. Vasu TS, Doghramji K, Cavallazzi R, Grewal R, Hiraini A, Leiby B, Markov D, Reiter D, Kraft WK, Witkowski T. Obstructive Sleep Apnea Syndrome and Postoperative Complications: Clinical Utility of the STOP-BANG Questionnaire. *Archives of Otolaryngology Head & Neck Surgery*. 2010; 136(10):1020-1024 [PMID: 20956751] <http://archotol.ama-assn.org/cgi/content/full/136/10/1020>
22. Stoch AS, Gargano C, Valentine J, Braun MP, Murphy MP, Fedgchin M, Majumdar A, Pequignot E, Gottesdiener KM, Petty KJ, Panebianco D, Dean D, Evans JK, Kraft WK, Greenberg HE. Double-Blind Crossover Study to Assess Potential Differences in Cytochrome P450 3A4 Activity in Healthy Subjects Receiving Ondansetron Plus Dexamethasone, With and Without Aprepitant. *Cancer Chemotherapy and Pharmacology*. 2011; 67(6):1313-21 [PMID: 20734049]
23. Kraft WK, Dysart K, Greenspan J, Gibson E, Kaltenbach K, Ehrlich M. Revised Dose Schema of Sublingual Buprenorphine in the Treatment of the Neonatal Opioid Abstinence Syndrome. *Addiction*. 2011; 106(3):574-80 [PMID: 20925688] <http://jdc.jefferson.edu/petfp/7/>
24. Dallob A, Luo WL Mabalot J, Ratcliffe L, Johnson-Levonas A, Schwartz JI, Dishy V, Kraft WK, de Hoon JN, Van Hecken A, de Lepeleire I, Radziszewski W, Wagner JA, Lai E. The Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Antiplatelet Activity of Clopidogrel or Aspirin. *Platelets*. 2011; 22(7):495-503. [PMID: 21526889]  
<http://jdc.jefferson.edu/petfp/14/>
25. Henwood PC, Kennedy KM, Thomson L, Galanis T, Tzanis G, Merli GJ, Kraft WK. The Incidence of Deep Vein Thrombosis Detected by Routine Surveillance Ultrasound in Neurosurgery Patients Receiving Dual Modality Prophylaxis. *Journal of Thrombosis and Thrombolysis*. 2011; 32(2):209-14. [PMID: 21505787] <http://jdc.jefferson.edu/petfp/25>
26. Hiraini A, Cavallazzi R, Vasu TS, Pachinburavan M, Kraft WK, Leiby B, Desimone J, Squires KE, Weibel S, Kane GK. Prevalence of Obstructive Lung Disease in HIV population: A Cross Sectional Study. *Respiratory Medicine*. 2011; 105(11):1655-61. [PMID: 21703841]

27. Anagnostis EA, Sadaka RE, Sailor LA, Moody DE, Dysart KC, Kraft WK. Formulation of Buprenorphine for Sublingual Use in Neonates. *Journal of Pediatric Pharmacology & Therapeutics*. 2011;16(4):281-4. [PMID: 22768012] <http://jdc.jefferson.edu/petfp/38/>
28. Reitman M, Dishy V, Moreau A, Denney W, Liu, C, Kraft WK, Mejia A, Matson M, Stoch A, Wagner J, Lai E. Pharmacokinetics and Pharmacodynamics of MK-5046, a Bombesin Receptor Subtype-3 (BRS-3) Agonist, in Healthy Subjects. *Journal of Clinical Pharmacology*. 2012;52 1306-1316 [PMID:22162541]
29. Cavallazzi R, Awe OO, Vasu TS, Hiraini A, Vaid U, Leiby B, Kraft WK, Kane GK. MELD Score for Predicting Outcome In Critically Ill Patients with Liver Cirrhosis. *Journal of Critical Care*. 2012; 27(4):424.e1-6 [PMID: 22227088]
30. Pasquinelli C, McPhee F, Eley T, Villegas C, Sandy K, Wendelburg P, Persson A, Hernandez D, Sheaffer A, Scola P, Marbury T, Lawitz E, Goldwater R, Rodriguez-Torres M, DeMicco M, Wright D, Charlton M, Kraft WK, Lopez-Talavera J, Grasela DM. Single and Multiple Ascending Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects With or Without Chronic Hepatitis C. *Antimicrobial Agents and Chemotherapy*. 2012; 56(4):1838-44. [PMID: 22290978]
31. Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA. The Effect of Multiple Doses of Rifampin and Ketoconazole on the Single Dose Pharmacokinetics of Ridaforolimus. *Cancer Chemotherapy and Pharmacology*. 2012; 69(5):1247-53 [PMID: 22290273]
32. Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and Pharmacodynamics of the Novel PAR-1 Antagonist Vorapaxar in patients with End-Stage Renal Disease. *The European Journal of Clinical Pharmacology*. 2012; 68(7):1049-56 [PMID: 22315147]
33. Pavri BD, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata J, Bilodeau M, Regan CP. Stump G, Fan L, Larson P, Mehta A, Wagner JA, Gutstein DE, Bloomfield D. MK-0448, a Specific Kv1.5 Inhibitor, Safety, Pharmacokinetics and Pharmacodynamic Electrophysiology Results in Experimental Animal Models and Humans. *Circulation: Arrhythmias & Electrophysiology*. 2012; 5(6):1193-201 [PMID: 23060423] <http://jdc.jefferson.edu/petfp/40>
34. Haleboua-De Marzio D, Kraft WK, Daskalakis C, Ying X, Hawke RL, Navarro VJ. Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Non-cirrhotic Hepatitis C Subjects After Single Oral Doses of Green Tea Extract. *Clinical Therapeutics*. 2012; 34:2279-2285 [PMID 23153661] [http://jdc.jefferson.edu/gastro\\_hepfp/17/](http://jdc.jefferson.edu/gastro_hepfp/17/)
35. Vaid U, Singer E, Marhefka GD, Kraft WK, Baram M. Poor Positive Predictive Value of McConnell's Sign on Transthoracic Echocardiography for Diagnosis of Acute Pulmonary Embolism. *Hospital Practice*. 2013;3(41)23-7 [PMID 23948618] <http://jdc.jefferson.edu/petfp/46>
36. Lawitz E, Sulkowski M, Jacobson I, Faruqi S, Kraft WK, Maliakkal B, Al-Ibrahim M, Ghalib R, Gordon S, Kwo P, Rockstroh J, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Safety, Antiviral and PK activity of Vaniprevir, a Hepatitis C Virus NS3/4A Protease Inhibitor, in Patients with HCV Genotype 1 Infection. *Antiviral Research*. 2013;99(3):214-20. [PMID 23747481]
37. Kraft WK, Chang P, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers W. Posaconazole Tablet Pharmacokinetics: Lack of Effect of Concomitant Medications Altering Gastric pH and Gastric Motility in Healthy Subjects. *Antimicrobial Agents and Chemotherapy*. 2014;58(7):4020-4025. [PMID: 24798274] <http://jdc.jefferson.edu/petfp/52>

38. Ng CM, Dombrowsky E, Lin HP, Barrett JS, Erlich ME, Moody DE, Kraft WK. Population Pharmacokinetic Model of Buprenorphine in Pediatric Patients with Neonatal Abstinence Syndrome. *Pharmacotherapy*. 2015 Jul;35(7):670-80. [PMID 26172282]
39. Gaballa S, Palmisiano N, Alpdogan O, Carabasi M, Filicko-O'Hara J, Kasner M, Kraft WK, Leiby B, Martinez-Outschoorn U, O'Hara W, Pro B, Rudolph S, Sharma M, Wagner JL, Weiss M, Flomenberg N, Grosso D. A 2-Step Haploidentical Versus Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. 2016 Jan;22(1):141-8. [PMID: 26415558]
40. Chalouhi N, Okabe T, Starke R, Daou B, Dalyai R, Bovenzi C, Anderson E, Barros G, Reese A, Jabbour P, Tjoumakaris S, Rosenwasser R, Kraft WK, Rincon F. Beta-Blocker Therapy and Impact on Outcome after Aneurysmal Subarachnoid Hemorrhage: a Cohort Study. *Journal of Neurosurgery*. 2016; 125(3):730-6. [PMID: 26799296]
41. Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. The Reversibility of Apixaban Anticoagulation with a Four Factor Prothrombin Complex Concentrate in Healthy Volunteers. *Clinical and Translational Science*. 2016;9:176–180. [PMID: 27304196]  
<http://onlinelibrary.wiley.com/doi/10.1111/cts.12398/full>
42. Kraft WK, Gilmartin J, Chappell DL, Gheyas F, Walker B, Nagalla S, Naik UP, Horrow J, Wrishko RE, Zhang S, Anderson MS. Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects. *Clinical and Translational Science*. 2016; 9(4):221-7. [PMID 27304196] <http://onlinelibrary.wiley.com/doi/10.1111/cts.12405/full>
43. Moore JN, Healy JR, Thoma BN, Peahota MM, Ahamadi A, Cavarocchi NC, Kraft WK. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane Oxygenation Therapy. *CPT: Pharmacometrics & Systems Pharmacology*. 2016;5(9):495-502. [PMID: 27639260] <http://onlinelibrary.wiley.com/wol1/doi/10.1002/psp4.12112/abstract>
44. Weinberg DS, Lin JE, Foster NR, Della'Zanna GJ, Umar A, Seisler DK, Kraft WK, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. *Cancer Prevention Research (Phila)*. 2017 Jun;10(6):345-354. [PMID: 28396341] <http://cancerpreventionresearch.aacrjournals.org/content/10/6/345.long>
45. Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Erlich ME. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. *New England Journal of Medicine*. 2017;376:2341-2348 [PMID [28468518](https://pubmed.ncbi.nlm.nih.gov/28468518/)]  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662132/>
46. Machado P, Stanczak P, Liu PJ, Moore J, Needleman L, Kraft WK, Forsberg F. Subdermal Ultrasound Contrast Dose Finding for Sentinel Lymph Node Identification in Healthy Volunteers. *Journal of Ultrasound in Medicine* 2018; 37:1611–1620 [PMID: 29205451]
47. Elia J, Ungal G, Kao C, Ambrosini A, De Jesus-Rosario N, Larsen L, Chivacci R, Wang T, Kurian C, Titchen K, Sykes B, Hwang S, Kuman B, Potts J, Davis J, Matalack J, Slattery E, Moorthy G, Zuppa A, Weller A, Byrne E, Li YR, Kraft WK, Hakonarson H. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. *Nature Communications*. 2018;9(1):4 [PMID: 29339723]  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770454/>
48. Marbach JA, Johnson D, Kloof J, Vira A, Keith S, Kraft WK, Margules N, Whellan D. The Impact of a Transition of Care Program on Acute Myocardial Infarction Readmission Rates. *American Journal of Medical Quality*. 2018; 33(5):481-486 [PMID: 29374965]  
<http://journals.sagepub.com/eprint/tUA4cB7eD8EUJggpAGip/full>

49. Moore J, Gastonguay M, Adeniyi-Jones S, Moody D, Ehrlich ME, Kraft WK. Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome. *Clinical Pharmacology and Therapeutics*. 2018 Jun;103(6):1029-1037. [PMID: 29516490]
50. Bashir B, Mantravadi S, Stickle DF, Chervoneva I, Kraft WK. Drug-drug interaction study of apixaban with cyclosporine and tacrolimus in healthy volunteers. *Clinical and Translational Science* 2018;11:590–596 [PMID: 29972633] <http://dx.doi.org/10.1111/cts.12580>
51. Davis J, Lane-Fall M, Kraft WK, Price D. Incorporation of quality and safety principles in Maintenance of Certification: An analysis of American Board of Medical Specialties Member Boards. *American Journal of Medical Quality*. 2019;34(2):176-181. [PMID: 29973059]
52. Wrishko RE, McCrea JB, Yee KL, Liu W, Panebianco D, Mangin E, Chakravarthy M, Martinez Cantarin MP, Kraft WK. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects. *Clinical Drug Evaluation*. 2019;39(5):441-451 [PMID: 30810914]
53. Snook AE, Baybutt TR, Xiang B, Abraham TS, Hyslop T, Zhan T, Kraft WK, Sato T, Waldman SA. Split Tolerance Permits Safe Ad5-GUCY2C-PADRE Vaccine-Induced T-cell Responses in Colon Cancer Patients. *Journal for ImmunoTherapy of Cancer*. 2019; 23;7(1):104. [PMID: 31010434]
54. Liu T, Lewis T, Moore JN, Kraft WK, Gauda E, Sartori D, Gobburu J, Ivaturi V. Could postnatal age-related uridine diphosphate glucuronic acid be a rate-limiting factor in the metabolism of morphine during the first week of life?. *CPT: Pharmacometrics & Systems Pharmacology*. 2019 Jul;8(7):469-477 [PMID 31044547] <https://doi.org/10.1002/psp4.12407>
55. McCrea JB, Macha S, Adedoyin A, Marshall WL, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch A, Iwamoto M. Pharmacokinetic Drug-Drug Interactions Between Letemovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus and Mycophenolate Mofetil. *Journal of Clinical Pharmacology*. 2019; 59(10) 1331–1339 [PMID 3099090]
56. Boelig RC, Zuppa AF, Kraft WK, Caritis S. Pharmacokinetics of Vaginal Progesterone in Pregnancy. *American Journal of Obstetrics and Gynecology*. 2019;221:263.e1-7 [PMID: 31211965]
57. Anderson MA, Gilmartin J, Fan L, Yee KL, Kraft WK, Triantafyllou I, Reitmann CL, Guo Y, Liu R, Fackler P, Iwamoto M. No Meaningful Drug Interaction with Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate Co-administration. *Antiviral Therapy*. 2019;24(6):443-450 [PMID: 31433304] <https://jdc.jefferson.edu/petfp/110/>
58. Rochania A, Lam E, Tanjuakio J, Hirose H, Kraft WK, Kaushal G. Simultaneous quantitative LC-MS method of ketamine, midazolam and their metabolites (dehydronorketamine, norketamine and 1hydroxymidazolam) for its application in patients on extracorporeal membrane oxygenation (ECMO) therapy. *Journal of Pharmaceutical and Biomedical Analysis*. 2020; 178:112947 [PMID 31708269]
59. Ankrom W, Bondisky P, Liu W, Palcza J, Liu W, Dockendorf M, Matthews C, Panebianco D, Reynders T, Wagner JA, Jakate A, Mesens S, Kraft WK, Marantonio EE. Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. *Clinical and Translational Science*. 2020; 13:462–472 [PMID 31899602] <https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12728>
60. Chervoneva I, Adeniyi-Jones, SC, Blanco F, Kraft WK. Development of an Abbreviated Finnegan Score for the Neonatal Abstinence Syndrome. *Journal of Perinatology* 2020; 40(7):1031-1040 [PMID: 32076111]

61. Lam E, Schaefer J, Zheng R, Zhang T, Kraft WK. Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. *Clinical and Translational Science*. 2020; 13:1244–1250. [PMID: 32407548]  
<https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12810>
62. Min KC, Kraft WK, Bondiskey P, Colon-Gonzalez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf M, Matthews C, Boinpally R. Atogepant Is Not Associated with Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults: Results from a Phase 1, Randomized, Controlled Trial. *Clinical and Translational Science*. 2020 Mar;14(2):599-605. [PMID: 33142014]  
<https://ascpt.onlinelibrary.wiley.com/doi/full/10.1111/cts.12917>
63. Smith JL, Lafferty M, Boelig RC, Carola D, Adeniyi-Jones SC, Kraft WK, Greenspan JS, Aghai ZH. Does Maternal Methadone Dose Correlate with The Severity of Neonatal Abstinence Syndrome? *American Journal of Perinatology*. 2020 Dec 15. doi: 10.1055/s-0040-1721693 [PMID 33321531]
64. Rochania A, Nuygen V, Becker R, Kraft WK, Kaushal G. Stability-indicating LC-MS Method for Determination of Stability of Extemporaneously Prepared Buprenorphine Oral Syringes. *The Journal of Pediatric Pharmacology and Therapeutics*. 2021;26(4):395-404 [PMID 34035685]  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139563/>
65. Eudy-Bryne R, Zane N, Adeniyi-Jones S, Gastonguay MR, Ruiz A, Kushal G, Kraft WK. Pharmacometric dose optimization of Buprenorphine in Neonatal Opioid Withdrawal Syndrome. Accepted, *Clinical and Translational Science*. 2021 Jun 3. doi: 10.1111/cts.13074. Online ahead of print. [PMID 34080312] <https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13074>
66. Boelig RC, Rochani A, Lam E, Kaushal G, Roman A, Kraft WK. Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy. *Clinical and Translational Science*. Online 26 July 2021 [PMID: 34310083]  
<https://doi.org/10.1111/cts.13111>
67. Liles, DK, Shah N, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crary SE, Kraft WK, Archer A, Cataldo, V, Hardesty BM, Idowu M, Desai PC, Ikeda AI, Puthenveetil G, Hassell KL, Sarnaik S, Paulose J, Lainé D, Purkayastha D, Nandal S, Kutlar A. Long Term Biological Effects in Sickle Cell Disease: Insights from the SUCCESSOR Study. [Letter]. *British Journal of Haematology*. 05 October 2021 [PMID 34611900]  
<https://onlinelibrary.wiley.com/doi/10.1111/bjh.17739>
68. Devlin LA, Young LW, Kraft WK, Wachman EM, Czynski A, Merhar SL, Winhusen T, Jones HE, Poindexter BB, Wakschlag LS, Slasbury AL, Matthews A, Davis JM. Neonatal Opioid Withdrawal Syndrome: Toward the Use of Buprenorphine in Infants. *Journal of Perinatology*. Published online 23 September 24, 2021 [PMID 34556799]
69. Weinberg DS, Foster NR, Della'Zanna G, Richmond E, McMurray RP, Kraft WK, Pallotto A, Kastenberg DM, Katz LC, Limburg PJ, Waldman SA. Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP-333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers. accepted *Cancer Biology & Therapy* [PMID 34632925]
70. Merli G, Kraft WK, Eraso L, Galanis T, Thompson L, Ouma G, Viscusi E, Stickle D, Gong J, Lam E. Apixaban Discontinuation for Invasive Or major Surgical procedures (ADIOS): A prospective cohort study. Accepted *Journal of Vascular Medicine* [PMID Pending] <https://jdc.jefferson.edu/medfp/315/>
71. Lam E, Lien YT, Kraft WK, Piraino B, Zhang J. Vancomycin Dosing During the Day Dwell Achieves Adequate Therapeutic Concentrations in Patients on Automated Peritoneal Dialysis. Accepted *Clinical and Translational Science* [PMID Pending] <https://doi.org/10.1111/cts.13182>

Full Pubmed citation list available at  
<https://www.ncbi.nlm.nih.gov/myncbi/walter.kraft.1/bibliography/public/>

#### **Editorials, Reviews, and Chapters:**

1. Kraft W, Steinberg M, Delnevo C. How to Help Your Patients Quit Smoking. IM: Internal Medicine. March 1999; 20:44-50
2. Greenberg HE, Mehdi F, VanBuren S, Waldman SA, Pequignot E, Kraft WK. Effects of Concomitant Administration of an Aluminum- and Magnesium-containing Antacid on the Absorption Profile of Loratadine, Chapter 97 in Clinical Immunology and Allergy in Medicine, Marone G, ed, JGC, Naples, Italy. 2003.
3. Kraft WK, Waldman SA, Weinberg D, Laine C. Thomas Jefferson University K30 Program Externship: Critical Review of the Medical Literature at The Annals of Internal Medicine. Clinical Research Perspective. Issue 1, March 2004
4. Kraft WK, Frick GS. The Bronchodilators. Hospital Practice Pulmonary Board Review, April 2007, Vol. 12 (1)
5. LaRusso J, Waldman SA, Kraft WK. Aprepitant For the Prevention Of Nausea And Vomiting Associated With Chemotherapy And Postoperative Recovery. Expert Review in Clinical Pharmacology. 2008; 1(1):27-37
6. Kraft WK, Waldman SA. Bridging the Therapeutic Continuum of Drug Development, Regulation and Use. Expert Review in Clinical Pharmacology. 2008; 1(1):1-3
7. Kraft WK, Diemer G. Managing Medication in the Perioperative Period, in Merli G, Weitz H, Eds., Medical Management of the Surgical Patient, 3rd. ed., Philadelphia, PA; Saunders; 2008
8. Kraft WK, Leone F. Asthma and COPD. In Waldman SA, Terzic A, Eds., Pharmacology and Therapeutics: Principles to Practice , 1st. ed., Saunders Elsevier; 2008
9. Mejia A, Kraft WK, Peptic Ulcer Disease and Reflux. In Waldman SA, Terzic A, Eds., Pharmacology and Therapeutics: Principles to Practice , 1st. ed., Saunders Elsevier; 2008
10. Kraft WK, Mejia A. Acid Peptic Diseases: Pharmacological Approach to Treatment. Expert Review in Clinical Pharmacology 2009; 2(3):295-314 [PMID 21822447]  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149864/>
11. Kraft WK, Desimone DC. Asthma, Chronic Treatment. In: Ebell MH, ed. Essential Evidence Plus. 1st ed. Hoboken, NJ: John Wiley and Sons.
12. Kraft WK, Neonatal Abstinence Syndrome. In: Ebell MH, ed. Essential Evidence Plus. 1st ed. Hoboken, NJ: John Wiley and Sons.
13. Kraft WK, Opioid Overdose. In: Ebell MH, ed. Essential Evidence Plus. 1st ed. Hoboken, NJ: John Wiley and Sons
14. Waldman SA, Kraft WK, Nelson T, Terzic A. Clinical Pharmacology: A Paradigm for Personalized Medicine. Biomarkers in Medicine 2009; 3(6), 679-84. [PMID: 20477706]
15. Waldman SA, Kraft WK, Nelson T, Terzic A. Experimental Therapeutics: A Paradigm for Personalized Medicine. Clinical and Translational Science 2009; 2(6): 436–438. [PMID: 20443936]

16. Colon Gonzalez F, Kraft WK. Pharmacokinetic Evaluation of Fosaprepitant Dimeglumine. *Expert Opinion in Drug Metabolism and Toxicology*. 2010 Oct;6(10):1277-86. [PMID: 20795794]
17. Galanis T, Kraft WK, Merli GJ. Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism In The Surgical Patient. In Cameron JL, ed. *Advances in Surgery*. Vol. 45, pg. 361-390, Mosby, 2011 [PMID: 21954699]
18. Kupetsky-Rincon E, Kraft WK. Healthy Volunteer Registries and Ethical Research Principles. *Clinical Pharmacology and Therapeutics*. 2012; 91(6):965-8. [PMID: 22609908] <http://jdc.jefferson.edu/petfp/36>
19. Kraft WK, van den Anker JN. Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome. *Pediatric Clinics of North America*. 2012; 59(5):1147-65 [PMID: 23036249] <http://jdc.jefferson.edu/petfp/39>
20. Okabe T, Kanzaria M, Rincon F, Kraft WK. Cardiac Abnormalities after Subarachnoid Hemorrhage: The Role of Cardiovascular Protection to Improve Clinical Outcome. *Neurocritical Care*. 2013;18(2):271-84. [PMID: 23238984]
21. Oppong Y, Kraft WK. Asthma, Chronic Treatment. In: Ebell MH, ed. *Essential Evidence Plus*. 2nd ed. Hoboken, NJ: John Wiley and Sons.
22. Marek E, Kraft WK. Ethanol Pharmacokinetics in Neonates and Infants. *Current Therapeutic Research*. 2014; 76: 90-97 [PMID: 25379066; PMCID: PMC4217115] <http://www.sciencedirect.com/science/article/pii/S0011393X14000228>
23. Kraft WK. Neonatal Abstinence Syndrome. In: Ebell MH, ed. *Essential Evidence Plus*. 2nd ed. Hoboken, NJ: John Wiley and Sons.
24. Moore JN, Healy JR. Kraft WK. Pharmacokinetic Evaluation of Posaconazole. *Expert Review of Clinical Pharmacology*. 2015; 8(3), 321–334 [PMID: 25916666]
25. Kraft WK, Stover MW, Davis JM. Neonatal Abstinence Syndrome: Pharmacologic Strategies for The Mother and Infant. *Seminars in Perinatology*. 2016; 40, 203-212 [PMID: 26791055] [doi:10.1053/j.semperi.2015.12.007](https://doi.org/10.1053/j.semperi.2015.12.007)
26. Kraft WK. Commentary on Hall, et al. *J Pediatr*. 2016 Mar;170:39-44.e1. *Yearbook of Pediatrics*, 2016;17:284-287
27. Filippone E, Kraft WK, Farber JL. The Nephrotoxicity of Vancomycin. *Clinical Pharmacology and Therapeutics*. 2017; Sep;102(3):459-469 [PMID 28474732] <http://onlinelibrary.wiley.com/doi/10.1002/cpt.726/epdf>
28. Mantravadi S, Ogdie A, Kraft WK. Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis. *Expert Opinion in Clinical Pharmacology*. 2017; 10(8):899-910 [PMID: 28490202] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348387/>
29. Shah AG, Peahota MM, Thoma BN, Kraft WK. Medication Complications in Extracorporeal Membrane Oxygenation. *Critical Care Clinics*. 2017;33: 897–920 [PMID: 28887935] <http://jdc.jefferson.edu/pharmacyfp/31/>
30. Kraft WK, Adeniyi-Jones SC, Erhlich ME. Buprenorphine for the Neonatal Abstinence Syndrome. (response to letter) *New England Journal of Medicine*. 2017; 377:996-998 [PMID: 28877016]
31. Kraft WK. Buprenorphine in the Neonatal Abstinence Syndrome. *Clinical Pharmacology and Therapeutics*. 2018 Jan;103(1):112-119 [PMID: 29105752]

32. Mangat AK, Schmörlzer GM, Kraft WK. Pharmacological and Non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). *Seminars in Fetal and Neonatal Medicine*. 2019 Apr;24(2):133-141. [PMID 30745219] <https://jdc.jefferson.edu/petfp/103/>
33. Jones HE, Kraft WK. Analgesia, opioids and other drug use during pregnancy and neonatal abstinence syndrome. *Clinics in Perinatology* 2019 Jun;46(2):349-366 [PMID 31010564]
34. Yen E, Kraft WK, Davis JM. Pharmacological Management of Neonatal Opioid Withdrawal Syndrome Chapter 37. *Yaffe & Aranda Pediatric Pharmacology*, 5<sup>th</sup> edition
35. Lam E, Bashir B, Chaballa M, Kraft WK. Drug Interactions between Direct-Acting Oral Anticoagulants and Calcineurin Inhibitors during Solid Organ Transplantation: Considerations for Therapy. *Expert Review of Clinical Pharmacology*. 2019 Aug;12(8):781-790. [PMID 31242782] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656586/>
36. Lam E, Lien YT, Kraft WK, Piraino B, Zhang J. Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. *Peritoneal Dialysis International*. 2020; 40(4):384-393 [PMID: 32065053] <https://journals.sagepub.com/doi/full/10.1177/0896860819889774>
37. Becker ML, Kraft WK. Seeking similarities rather than differences with adults to aid in therapeutic advancement for children. *Clinical Pharmacology and Therapeutics*. 2021; 110(1):11-14. [PMID: 34148235] <https://jdc.jefferson.edu/petfp/133>

**Abstracts:**

1. Wagner JA, Kraft WK, Burke J, Wong P, Gleave M, Wildonger L, Ebel D, VanBuren S, Gottesdiener K, Waldman SA, Greenberg HE. The Cox-2 Inhibitor Etoricoxib Did Not Alter the Anti-Platelet Effects Of Low-Dose Aspirin In Healthy Volunteers. *American College of Rheumatology*, 2001
2. Kraft WK, Bonner HS, Chervoneva I, Waldman SA, Shaw LM, Greenberg HE. The Pharmacokinetics (PK) Of Three Subcutaneously (SC) Administered Formulations of Amifostine. *American Society for Clinical Pharmacology and Therapeutics meeting in Atlanta, GA, March 2002*
3. Burke J, Greenberg HE, Gleave M, Kraft WK, Pitari GM, VanBuren S, Gottesdiener K, Wagner JA, Waldman SA. Relationship of Cyclooxygenase (COX)-Dependent Human Platelet Aggregation and Arachidonic Acid (AA) Concentration. *American Society for Clinical Pharmacology and Therapeutics, Atlanta, GA, March 2002*
4. Kraft WK, Waldman SA, Pequignot E, Greenberg HE. The absorption of loratadine is modified by concomitant administration of an aluminum-magnesium containing antacid. *American Society for Clinical Pharmacology and Therapeutics meeting in Atlanta, GA, March 2002*
5. Greenberg HE , Mehdi F, VanBuren S, Waldman SA, Pequignot E, Kraft WK. Effects of Concomitant Administration of an Aluminum and Magnesium-containing Antacid on the Absorption Profile of Loratadine. *EAACI, Naples, Italy, June 2002*
6. Petty KJ, Majumdar A, Orlowski LH, Panebianco D, Goldberg MR, Murphy, MG, Gottesdiener KM, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Lack Of Effect Of Aprepitant On The Pharmacokinetics Of Granisetron. *American Society for Clinical Pharmacology and Therapeutics, Washington, DC, March 2003*
7. Tiyyagura SR, Waldman SA, Kraft WK. Torsades des Pointe (TdP) Associated with Methadone Maintenance Therapy (MMT) In A Patient With Hepatitis-Induced Cirrhosis. *American Society for Clinical Pharmacology and Therapeutics meeting in Miami, FL, March 2004*

8. Frick GS, Blum RA, Kovacs SJ, Vitow C, Stewart JA, Kraft WK. Prevalence Of The Slow Metabolizer (SM) Phenotype And Single Dose Pharmacokinetics (PK) Of Desloratadine (DCL) In A Population Of Healthy Adults. American Society for Clinical Pharmacology and Therapeutics meeting in Miami, FL, March 2004
9. Blum RA, Frick GS, Kovacs SJ, Meeves S, Georges GC, Kraft WK. Clinical Implications Of The Desloratadine Slow Metabolizer (DSM) Phenotype Based On Pharmacokinetic (PK) Principles. The American Academy of Allergy, Asthma and Immunology meeting in San Francisco, CA, March 2004
10. Kraft WK, Blum RA, Frick GS, Vitow C, Stewart JA, Kovacs SJ. Pharmacokinetics (PK) of Multiple Oral Doses of Desloratadine (DCL) and Fexofenadine (FEX) in a Population of Healthy Adults Identified Phenotypically as Desloratadine Slow Metabolizers (DSMs) American Society for Clinical Pharmacology and Therapeutics meeting in Orlando, FL, March 2005
11. Li G, Waldman SA, Greenberg HE, Kraft WK. The Pharmacokinetics Of Taurolidine Metabolites In Healthy Volunteer The. American College of Clinical Pharmacology meeting in Cambridge, MA, September 2006
12. Hayes E, Almario C, Pizzi L, Kraft WK, Baxter J. Low molecular weight heparin, the most cost effective treatment of venous thromboembolism. The Society for Maternal Fetal Medicine 27th Annual Scientific Meeting in San Francisco, CA, February 2007
13. Henwood PC, Merli GJ, Rosenwasser RH, Tzanis G, Thomson L, Fink J, Kraft WK. Prophylaxis, screening and the incidence of periprocedural deep vein thrombosis among neurosurgical patients at an academic medical center. Society for Vascular Medicine and Biology 18th Annual Scientific Sessions, Baltimore, MD, June 2007
14. Gong JP, Burke J, Blanchard RL, Dicipinigaitis P, Yan X, Palcza J, Bradstreet TE, Kraft WK, Cough Response To Inhaled Capsaicin Following A Blinded, Oral, Single Dose Of Codeine, Dextromethorphan, Or Placebo In Healthy Males. American Society for Clinical Pharmacology and Therapeutics meeting in Orlando, FL, April 2008
15. Kraft WK, Dysart K, Gibson E, Greenspan J, Damle V, Kaltenbach K, LaRusso J, Moody D, Ehrlich M. First Use of Sublingual Buprenorphine for Treatment of the Neonatal Abstinence Syndrome: A Randomized Trial. Society for Pediatric Research Meeting, Hawaii, May 2008
16. Wu D, Kraft WK, Ehrlich ME, Barrett JS. Sublingual bioavailability of buprenorphine in newborns with neonatal abstinence syndrome--a case study on physiological and developmental changes using SIMCYP. American College of Clinical Pharmacology meeting, Philadelphia, PA, Sept. 2008 <http://jdc.jefferson.edu/petfp/24/>
17. Lawitz E, Sulkowski M, Jacobson I, Faruqui S, Kraft W, Maliakkal B, Al-Ibrahim, Reem Ghalib M, Gordon S, Kwo P, Rockstroh J, Miller M, Hwang P, Gress J, Quirk E. Safety, Tolerability and Antiviral Activity of MK-7009, a Novel Inhibitor of the Hepatitis C Virus NS3/4A Protease, in Patients with Chronic HCV Genotype 1 Infection. American Association for the Study of Liver Diseases meeting, Nov. 2008 in San Francisco, CA
18. Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC, Grasela DG. BMS-790052 is a Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study. American Association for the Study of Liver Diseases meeting, Nov. 2008 in San Francisco, CA
19. Schwartz J, Mabalot J, Luo L, Dallob A, Kraft WK, Wagner J, Lai E. "Laropiprant Does Not Alter the Antiplatelet Activity of Aspirin." Presented at the American Heart Association meeting Nov. 2008 in New Orleans, LA

20. Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC, Grasela DG. BMS-790052 is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study.” Presented at the The Asian Pacific Association for the Study of the Liver Meeting Feb. 2009 in Hong Kong
21. Nettles RE, Chien C, Chung E, Persson A, Gao M, Belema M, Meanwell N, DeMicco M, Marbury T, Goldwater P, Northup P, Coumbis J, Kraft WK, Charlton M, Lopez-Talavera JC, Grasela DG. BMS-790052 is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for Patients with Chronic HCV Infection: Results from a Proof-of-concept Study. 13th International Symposium on Viral Hepatitis and Liver Disease March 2009 in Washington, D.C.
22. Omicioli V, Daskalakis C, Louis D, Rabinowitz C, Maio V, Kraft WK “Comparison of Transdermal and Oral Estrogen Hormone Therapy and Risks of Venous Thromboembolic Events” 20th Annual Meeting of the North American Menopause Society, San Diego, CA Sept 30-Oct 3, 2009
23. Halegoua-De Marzio D, Kraft WK, Greenbaum L, Xie Y, Hawke R, Navarro VN. Safety and Tolerability of Single Dose Green Tea Extract Epigallocatechin Gallate (EGCG) in Cirrhotic and Non-cirrhotic Hepatitis C Patients. Digestive Diseases Week, San Diego, CA, 2012
24. Wu D, Kraft WK , Ehrlich ME, Dombrowsky E, Barrett JS Population pharmacokinetic modeling of buprenorphine in newborns with neonatal abstinence syndrome. American Society for Clinical Pharmacology and Therapeutics meeting in Washington, D.C. March 2012
25. Gentzler R, Kraft WK, Leiby B, Filicko-O'Hara J. Comparing Prognosis Estimates of Cancer Patients and Their Oncologists. Presented in *2012 ASCO Annual Meeting Proceedings I*
26. Kraft WK, Chang P, van Iersel MLPS, Waskin H, Krishna G, Kersemaekers W. Effect of Concomitant Medications Affecting Gastric pH and Motility on Posaconazole (POS) Tablet Pharmacokinetics (PK). ICAAC, San Fransico, September 2012 <http://jdc.jefferson.edu/petfp/37>
27. Perez A, Galanis T, Eraso EH, Kraft WK, Templin M, Louis DZ, Merli GJ. Characterization of venous thromboembolism stratified by medical thromboprophylaxis: Experience in a free standing neurosciences hospital. Society for Vascular Medicine meeting, Minneapolis, MN, June 14, 2012.
28. D’Ascenzo JD, Franta KJ, Kraft WK, Thomson LJ. A Potential Interaction between Melatonin and Warfarin: Is It Worth Losing Sleep Over? ASHP (American Society of Health System Pharmacists) Midyear Clinical Meeting, Las Vegas, NV, Dec. 5, 2012
29. Anderson MS, Gilmartin J, Mitselos A, Laethem T, van Bortel L, Kraft WK, Guo Y, Dockendorf MF, Wagner JA, Butteron JR. Effect of Ritonavir (RTV) and Tenofovir (TDF) on the Pharmacokinetics of MK-1439, a Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Interscience Conference on Antimicrobial Agents & Chemotherapy (ICAAC 2013), Denver, CO, Oct. 11, 2013
30. Eraso EH, Galanis T, Kipp K, Kraft WK , Palladino M, Perez A, Ferebee–Spruill K, Merli G, Swift B, Thomson L, Vining B. The Impact of Community Use of Novel Oral Anticoagulants on an Academic Medical Center. The Anticoagulation Forum, Phoenix, AZ, May 5, 2013 <http://jdc.jefferson.edu/petfp/42/>
31. Palladino M, Thomson L, Eraso EH, Merli G, Galanis T, Kraft WK , Perez A. Developing a Transition of Care Model to Safely and Effectively Manage Complex Vascular Diseases. The Anticoagulation Forum, Phoenix, AZ, May 5, 2013

32. Fielder AL, Collier JK., Hutchinson M, Haslam RR, Lu N, Adeniyi-Jones S, Ehrlich M, Kraft WK. Neonatal abstinence syndrome (NAS) in methadone exposed infants: role of genetic variability. CPDD Scientific Meeting, San Juan, PR, June 18, 2014 <http://jdc.jefferson.edu/petposters/3/>
33. Okabe T, Kanzaria M, Rincon F, Leiby B, Fred Rincon MD, Kraft WK. Impact of Preadmission Beta-blocker Use on Cardiac Abnormalities and In-hospital Mortality in Patients with Aneurysmal Subarachnoid Hemorrhage. 2014 International Heart & Brain Summit, Columbus, Ohio, October 25, 2014
34. Marshall WL, Badshah C, Liu F, Kraft WK, Gonzales-Colon F, van Schanke A, Udo de Haes J, Kantesaria B, Cho C, Hulskotte E, Butterson JR, Marcantonio EE. No Evidence of a Drug-Drug Interaction between Letermovir (MK-8228) and Mycophenolate Mofetil. Presented at ASMBT meeting, San Diego, Feb. 2015. Biol Blood Marrow Transplant. 2015;2(21):S243 <http://jdc.jefferson.edu/petfp/61>
35. Sama AR, Leiby BE, Swartz K, Schoppe J, MacKenzie AR, Kraft WK, Chapman AE. A screening tool to identify "FIT" geriatric oncology patients. Presented Online for American Society of Clinical Oncology, 2015 Meeting
36. Moore J, Healy J, Thoma B, Peahota M, Cavarocchi, Kraft WK. Modeling Vancomycin Pharmacokinetics in Patients Undergoing Extracorporeal Membrane Oxygenation Therapy. The American Conference on Pharmacometrics (ACoP), Crystal City, VA, October 4th – 7th, 2015
37. Marek E, Adeniyi-Jones SC, Roke L, DeCerbo TE, Cordell RL, Monks PS, Kraft WK. Ethanol Pharmacokinetics in Neonates Secondary to Medication Administration. American Academy of Pediatrics meeting in Washington DC, October 24 2015 <http://jdc.jefferson.edu/petposters/1/>
38. Adam E. Snook AE, Baybutt TR, Mastrangelo MJ, Lewis NL, Goldstein SD, Kraft WK, Oppong YD, Hyslop T, Myers RE, Alexeev V, Eisenlohr LC, Sato T, Waldman SA. A Phase I Study of Ad5-GUCY2C-PADRE in Stage I and II Colon Cancer Patients. Society for Immunotherapy of Cancer meeting, National Harbor, MD, November 2015 <http://jdc.jefferson.edu/petposters/2/>
39. Jones G, De Jesus-Rosario N, Kao C, Ambrosini A, Larsen L, Chiavacci R, Pallotto A, Kurian C, Titchen K, Sykes B, Kraft WK, Hakonarson H, Elia J. Exploratory Dose-Escalation Study of NFC-1 in ADHD Adolescents With Glutamatergic Gene Network Variants. American Academy of Child and Adolescent Psychiatry meeting, San Antonio, TX, Oct. 31, 2015
40. Kraft WK, Thomson L, Oppong Y, Bachman B, Chervoneva I, Nagalla S. 4-Factor Prothrombin Concentrate Reverses Apixaban Inhibition of Thrombin Generation in Healthy Volunteers. American Society for Clinical Pharmacology and Therapeutics meeting in San Diego, CA. March 2016
41. Tran BD, Sima J, Moorthy GS, Jason Healy J, Kraft WK, Zuppa AF. An Investigation into Ketamine and Norketamine Stability in Whole Blood at Room Temperature. Late Breaker presentation at American Society for Clinical Pharmacology and Therapeutics meeting in San Diego, CA. March 2016
42. Kraft WK, Gilmartin J, Chappell DL, Gheyas F, Nagalla S, Naik UP, Wrishko RE, Zhang S, Anderson MS. Vorapaxar Does Not Increase Bleeding Time. Arteriosclerosis, Thrombosis, and Vascular Biology/ Peripheral Vascular Disease 2016 Scientific Sessions, Nashville, TN, May 5-7, 2016
43. Machado P, Stanczak P, Liu PJ, Needleman L, Moore J, Kraft WK, Vizza K, Forsberg F. Dose finding, cross over study of subdermal ultrasound contrast agent injection for breast imaging in healthy volunteers. Presented at The American Institute for Ultrasound in Medicine meeting in Orlando, FL 2017

44. Moore J, Gastonguay M, Adeniyi-Jones S, Moody D, Kraft WK. Population Pharmacokinetic and Pharmacodynamic Analysis of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome. Accepted to American Society for Clinical Pharmacology and Therapeutics meeting in Washington, DC. March 2017. Clin Pharmacol Ther 2017(101;S1) PI-099  
<http://jdc.jefferson.edu/petposters/4/>
45. Kraft WK, Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Erhlich ME. A Randomized Controlled Trial of Sublingual Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. Platform Presentation at Pediatric Academic Societies Meeting, San Francisco, CA. May 7, 2017
46. Machado P, Stanczak P, Liu PJ, Eisenbrey RJ, Needleman L, Moore J, Berger A, Lazar M, Willis A, Kraft WK, Forsberg F. Sentinel Lymph Node Identification Using Subdermal Ultrasound Contrast Agent Injection. The American Institute for Ultrasound in Medicine meeting, NYC, NY, March 25, 2018
47. Bashir B, Tran BD, Mantravadi S, Stickle DF, Chervoneva I, Kraft WK. Drug-Drug Interaction Study Of Apixaban With Cyclosporine Or Tacrolimus: Results From A Phase 1, Randomized, Open-Label, Crossover Study In Healthy Volunteers. American Society for Clinical Pharmacology and Therapeutics meeting, Orlando, FL March 2018 <http://jdc.jefferson.edu/petposters/5/>
48. Adeniyi-Jones SC, Chervoneva I, Greenspan JS, Abatemarco D, Kaltenbach K, Erhlich, Kraft WK. Buprenorphine for Treatment of Neonatal Abstinence Syndrome Following In Utero Exposure to Opioids and Benzodiazepines. Eastern Society for Pediatric Research Meeting, 2018
49. Liu T, Lewis T, Moore JN, Kraft WK, Gauda E, Sartori D, Gobburo J, Ivaturi V. Uridine diphosphate glucuronic acid is a potential rate-limiting factor in the metabolism of morphine during the first week of life. Presented at American College of Pharmacometrics meeting, San Diego, CA, October 2018
50. Zane NR, Kraft WK, Zuppa AF, Gastonguay MR. Clinical Trial Dose Optimization of Buprenorphine for Neonatal Abstinence Syndrome Using an Adaptive Monte Carlo Simulation. Oral presentation at American College of Pharmacometrics meeting, San Diego, CA, October 2018; J Pharmacokinetic Pharmacodyn 45,S82-S83 (2018) <https://link.springer.com/article/10.1007/s10928-018-9606-9>
51. Rochani A, Lam E, Tanjuakio J, Hirose, Kraft WK, Kaushal G. LC-MS Method Development of Midazolam and Ketamine: Application to a Pharmacokinetic Study in Patients on Extracorporeal Membrane Oxygenation Therapy. Presented at the American Association of Pharmaceutical Scientists, November 2018, Washington D.C.
52. Jones JF, Smith JL, Kraft WK, Aghai ZH, Greenspan JS, Adeniyi-Jones SC. Retrospective Examination of Buprenorphine Treatment for Infants with In Utero Benzodiazepine and Opioid Exposure. (REB-TIBE). Presented at Neonatal Hot Topics, Washington, DC, December 3, 2018
53. Smith JL, Lafferty M, Carola D, Adeniyi-Jones SC, Kraft WK, Aghai ZH. Does Maternal Methadone Dose Correlate With The Severity of Neonatal Abstinence Syndrome? Presented at Neonatal Hot Topics, Washington, DC, December 3, 2018
54. Boelig RC, Zuppa A, Kraft WK, Caritis S. Pharmacokinetics of vaginal progesterone in pregnancy. Society for Maternal Fetal Medicine Annual Pregnancy Meeting. 2019 February Las Vegas, NV
55. Favara MT, Smith JL, Lafferty M, Carola D, Adeniyi-Jones SC, Kraft WK, Greenspan J, Aghai ZH. Growth Retardation in Infants with Neonatal Abstinence Syndrome Admitted to the Neonatal Intensive Care Unit. ESPR 2019/Eastern Society for Pediatric Research Scientific Meeting

56. Adeniyi-Jones SC, Chervoneva I, Blanco F, Kraft WK. Development and Analysis of an Abbreviated MOTHER-Finnegan Score (MFNAS) for The Neonatal Abstinence Syndrome (NAS). ESPR 2019/Eastern Society for Pediatric Research Scientific Meeting
57. Ankrom W, Bondisky P, Liu W, Palcza J, Panebianco D, Dockendorf M, Matthews C, Kraft WK, Wagner J. Multiple, Once-Daily, Oral Doses of 150 mg Ubrogepant Administered for 28 Days Are Generally Well Tolerated, With No Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males. American Academy of Neurology meeting, May 2019, Philadelphia, PA
58. Shah N, Boccia R, Kraft WK, Hardesty B, Paulose J, Laine D, Purkayastha D, Nandal S, Kutlar A. Successor Study: Treatment And Health Care Resource Utilization Patterns By Sickle Cell Patients Who Participated In The Sustain Study In The United States. Accepted to the ISPOR meeting May 21, 2019
59. Shah N, Boccia R, Kraft WK, Hardesty B, Paulose J, Laine D, Purkayastha D, Bhor M, Achebe M, Cataldo V, Kutlar A. Rate of Sickle Cell Pain Crises in Patients Who Previously Participated in the SUSTAIN Trial in the United States: The SUCCESSOR Study. AMCP Annual Meeting, San Diego, California, March 25-28, 2019.
60. Lam E, Eraso L, Galanis T, Kraft WK, Ouma G, Thompson L, Viscusi E, Stickle D, Gong J, Adams S, Merli G. Apixaban Discontinuation Prior to Major Surgery: Results from a Prospective Single Center Study. American College of Cardiology meeting March 2019 in New Orleans, LA
61. Liles, DK, Shah N, Scullin B, Gordeuk VR, Smith WR, Kanter J, Achebe MM, Boccia R, Crar SE, Kraft WK, Archer A, Cataldo, V, Hardesty BM, Idowu M, Desai PC, Ikeda AI, Puthenveetil G, Hassell KL, Sarnaik S, Paulose J, Lainé D, Purkayastha D, Nandal S, Kutlar A. SUCCESSOR: A Multicenter Retrospective Non-interventional Follow-Up Study in Patients with Sickle Cell Pain Crises Who Previously Participated in the SUSTAIN Trial in the United States. 24th Congress of the European Hematology Association. June 15, 2019
62. Shah N, Boccia R, Kraft WK, Cataldo V, Paulose J, Laine D, Purkayastha D, Kutlar A. SUCCESSOR Study: Baseline Demographics of the Retrospective, Noninterventional Follow-Up Study in a Subset of Patients With Sickle Cell Pain Crises Who Previously Participated in SUSTAIN in the United States. 13th Annual Sickle Cell Disease Research and Educational Symposium and 42nd National Sickle Cell Disease Scientific Meeting June 9, 2019
63. Rochania A, Lamb E, Tanjuakioc J, Hirose H, Kraft WK, Kaushal G LC-MS Method Development for Quantitation of Midazolam, Ketamine and their Metabolites (Nor ketamine, Dehydro-Nor ketamine and 1-Hydroxymidazolam): Application to a Pharmacokinetic Study in Patient on Extracorporeal Membrane Oxygenation Therapy. Accepted for presentation at American Academy of Pharmaceutical Scientists, Pharm 360, San Antonio, TX Nov. 3-6, 2019
64. Lien YT, Lam E, Vozmediano V, Rochani A, Kaushal G, Tanjuakio J, Thoma BN, Hirose H, Kraft WK, Schmidt S. Ketamine Population Pharmacokinetics in Critically Ill Patients on Extracorporeal Membrane Oxygenation Therapy. Accepted for presentation at the American College of Clinical Pharmacology, Chicago, IL, Sept. 15-17, 2019
65. Lam E, Schaefer J, Zheng R, Zhan T, Kraft WK. Effect of once-weekly rifapentine and isoniazid on the pharmacokinetics of twice-daily doravirine in healthy volunteers. Accepted for Presentation at American Society for Clinical Pharmacology and Therapeutics Meeting in March 2020
66. Min CK, Kraft WK, Bondisky P, Colon-Gonzalez F, Liu W, Xi J, Panebianco D, Mixson L, Dockendorf M, Matthews CV, Boinpally R. Multiple, Once-Daily, Oral Doses of 170 mg Atogepant for 28 Days Are Safe and Well Tolerated With No Clinically Significant Effect on Alanine Aminotransferase in Healthy Adults. Presented at the 62nd Annual American Headache Society Scientific Meeting (AHS 2020)

67. Hand DJ, Giang Copeland N, Dewey J, Mancuso F, Short, VL, Kraft WK, Adeniyi-Jones S, Abatemarco D. Gabapentin exposure and the time course of neonatal abstinence syndrome among methadone-exposed neonates. Accepted for an oral presentation 6/22/2020 at the College on Drug Dependence 2020 Annual Meeting, Hollywood, FL
68. Boelig RC, Lam E, Rochani A, Kaushal G, Roman A, Kraft WK. Noninvasive amniotic fluid sampling to establish PK of azithromycin in pregnancy. Presented at American Society for Clinical Pharmacology and Therapeutics Annual Meeting, 2021
69. Bibi S, Gaddis N, Terrin N, Singh R, Lester B, Johnson E, Kraft WK, Davis JM. Association of Polygenic Risk Scores with Pharmacotherapy for Neonatal Abstinence Syndrome. Pediatric Academic Societies meeting 2021
70. Yamada R, Kano-Lueckerath M, Kraft WK. Differences in Obstetric Care between Japan and the US: A Qualitative Analysis of Blogs. Accepted for presentation ACOG Annual Clinical and Scientific Meeting (ACSM): Personalizing Care: A Way to the Future. April 30-May 2, 2021
71. Randolph P, Matthews RP, Kim N, Liu Y, Rudd DJ, Garrett G, Gilmartin J, Kraft WK, Vargo R, Stoch SA, Iwamoto M. No Drug Interaction Effect Of Pantoprazole On Doravirine/Islatravir Pharmacokinetics. Submitted to CROI 2022

**Lectures by Invitation (Thomas Jefferson University or Hospital):**

- |          |                                                                                                                             |
|----------|-----------------------------------------------------------------------------------------------------------------------------|
| 6/10/99  | Department of Medical Grand Rounds, "Bioterrorism"                                                                          |
| 6/13/03  | Current Trends in Antithrombotic Therapy CME Symposium, "Duration of Anticoagulation"                                       |
| 9/16/03  | Division of Hematology (Cardeza Foundation) Grand Rounds, "Duration of Anticoagulation"                                     |
| 11/22/04 | Thomas Jefferson University Faculty Development Seminar, "Teaching Evidence Based Medicine at the Bedside"                  |
| 6/9/06   | Preoperative Evaluation and Post-Operative Care CME Symposium, "Preoperative Medications: Management Strategies"            |
| 1/25/07  | Division of Rheumatology Grand Rounds, "Current Issues in Anticoagulation"                                                  |
| 6/12/09  | Department of Neurosurgery Grand Rounds, "Venous Thromboembolism Prophylaxis in the Neurosurgical Patient"                  |
| 1/10/12  | Faculty Development Lecture, "Obtaining Industry Support of Investigator Initiated Research Proposals" (workshop organizer) |
| 9/19/13  | Faculty Development Lecture, "How to Build a Career in Clinical Research" (workshop organizer)                              |
| 9/28/13  | MD/PhD Retreat, Panelist, "Challenges Facing Physician Scientists in the 21st Century" (speaker)                            |
| 3/13/14  | Medical Education Research Interest Group, "How the IRB Looks at Medical Education Projects".                               |
| 2/2/15   | Faculty Development Lecture, "The Five Things You Need to Know Before You Do Clinical Research" (workshop organizer)        |

- 2/13/15 Faculty Development Lecture, "Conducting Clinical Research: How to Navigate the IRB" (workshop organizer)
- 9/22/15 Faculty Development Lecture, "How JCRI Can Help You Conduct Clinical Research"
- 3/2/18 Learning Collaborative Speaker, "Neonatal Abstinence Syndrome", Division of Substance Abuse Programs
- 1/26/21 Sydney Kimmel Cancer Center Boot Camp speaker, "Ethics of Clinical Research"
- 2/8/21 Sydney Kimmel Cancer Center Boot Camp speaker, "Pharmacokinetics in Clinical Trials"
- 7/31/21 Jefferson Northeast EM/IM Residency research retreat speaker, "IRB guidance for scholarly projects"

**Lectures by Invitation (External):**

- 1/17/01 Medical Grand Rounds, "Airway Remodeling and Collagen Deposition in Asthma", Veterans Affairs Medical Center, Wilmington, DE
- 12/5/01 Medical Grand Rounds, "Is There an Epidemic Of Primary Hyperaldosteronism", Veterans Affairs Medical Center, Wilmington, DE
- 12/3/03 Medical Grand Rounds, "Duration of Anticoagulation", Veterans Affairs Medical Center, Wilmington, DE
- 9/11/04 Lower Shore Symposium, American College of Physicians, Delaware Chapter, "Idiopathic Deep Vein Thrombosis/Pulmonary Embolus: What the Data Tells Us About the Duration of Anticoagulation", Rehoboth Beach, DE
- 3/8/07 Oral presentation of "Trial of Buprenorphine for the Treatment of Neonatal Abstinence Syndrome", National Institute of Drug Abuse Conference Pharmacotherapy Research for the Treatment of In-Utero Substance Exposed Neonates: Advances and Future Directions. Rockville, MD
- 3/24/07 Co-chair and moderator, Late Breaking Abstract Session, American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Anaheim, CA
- 4/5/08 Co-chair and moderator, Late Breaking Abstract Session, American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Anaheim, CA
- 9/12/08 Visiting FDA lecturer, "Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome", Office of Clinical Pharmacology, CDER, FDA, White Oak, MD
- 3/20/09 Co-chair and moderator, Oral Session "Pharmacodynamic Modeling", American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC
- 4/8/09 Association of Clinical Research Professionals Seminar, "Phase 1 Trials in Healthy Volunteers", Lambertville, NJ
- 6/24/10 Featured Speaker, "Future Trends in the Treatment of Neonatal Abstinence Syndrome", 2010 Summit on Substance Exposed Newborns: Collaborative Approaches to a Complex Issue. Alexandria, VA

- 2/24/11 Medical Grand Rounds, "Phase 1 Research and Healthy Volunteers", Cooper University Hospital, Camden, NJ
- 6/1/11 14th Annual Neonatal Advanced Practice Nursing Forum, "New Agents, New Horizons in the Pharmacologic Management of Substance - Exposed Newborns", Washington, D.C.
- 12/20/11 Visiting Speaker, "Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome", Division of Clinical Pharmacology, Indiana University School of Medicine
- 3/16/12 Symposium Chair and Presenter, "Optimizing Pediatric Therapeutics by Applying Lessons from Adult Drug Development", American Society of Clinical Pharmacology and Therapeutics Annual Meeting, Washington, DC
- 4/26/12 Speaker and Discussant, "The Human Research Participant in Today's Early Phase Research & Updates on National Registry Initiatives", Association of Clinical Pharmacology Units Annual Meeting, Bethesda, MD
- 5/3/12 Speaker and Discussant, "Addressing Current Recruitment and Retention Challenges within Pediatric Clinical Trials" and "Optimizing Pediatric Drug Development", at 8th Annual Pediatric Clinical Trials meeting, Philadelphia, PA
- 5/9/12 Division of Hematology Research Conference, "Optimizing Pediatric Drug Development", Thomas Jefferson University
- 9/23/12 Speaker and Discussant, "Safety Challenges and Developing Models for Emergency Response Coverage in First in Human Trials", American College of Clinical Pharmacology Annual Meeting, San Diego, CA
- 11/4/12 Speaker and Discussant, "Bridging Adult and Pediatric Conditions: Biomarkers in Pediatric Drug Development", American Heart Association Scientific Sessions 2012, Los Angeles, CA
- 11/16/12 Speaker, "Best Practices and Resources for Preventing Dual Enrollment in Clinical Trials", GCP Compliance and Quality Oversight Conference, New Brunswick, NJ
- 2/25/13 Speaker, ""Novel Therapies in Treatment of Neonatal Abstinence Syndrome", Translational Science Research Seminar, Nemours/A.I. duPont Hospital for Children, Wilmington, DE
- 5/15/13 Faculty Speaker, "Substance Exposure 101: Frequency and Neonatal Impact by Agent" Vermont Oxford Network Webinar Curriculum, *Controversies in Caring for Infants and Families Affected by Substance Abuse Disorders and Neonatal Abstinence Syndrome* <http://www.vtoxford.org/quality/inicq/nascontroversies.aspx>
- 5/29/13 Speaker, "Pharmacology Review: Risks and Benefits of Methadone, Morphine, Buprenorphine, Clonidine, and/or Phenobarbital". 16th Annual Neonatal Advanced Practice Nursing Forum Preconferences A and B, Washington, DC
- 5/30/13 Speaker, "Controversies in the Treatment of Neonatal Abstinence Syndrome: Methadone, Morphine, Buprenorphine, Clonidine, Phenobarbital or Bust?" 16th Annual Neonatal Advanced Practice Nursing Forum, Washington, DC
- 7/14/13 Faculty Speaker, "Examining the Evidence: Controversies in the Pharmacologic Management" Vermont Oxford Network Webinar Curriculum, *Controversies in Caring for Infants and Families Affected by Substance Abuse Disorders and Neonatal Abstinence Syndrome*

- 1/22/14 Faculty Speaker, "Toxidromes: Making the best treatment decisions" Vermont Oxford Network Webinar Curriculum, Structuring Success in the Care of Infants and Families Affected by Neonatal Abstinence Syndrome
- 3/6/14 Speaker, "Pharmacologic Therapies for the Neonatal Abstinence Syndrome". Neofest 2014, Cincinnati Children's Hospital, University of Cincinnati School of Medicine
- 8/26/14 Speaker, "Current Pharmacologic Approaches to the Treatment of Neonatal Abstinence Syndrome" Christiana Hospital Grand Rounds, Newark, DE
- 9/13/14 Workshop organizer and session chair, "Opioid Prescribing: Reducing the Risks", American College of Clinical Pharmacology scientific meeting, Atlanta, GA
- 9/14/14 Symposium organizer and session chair, "Real-world, Large-scale Implementation of Pharmacogenetic-guided Drug Dosing", American College of Clinical Pharmacology scientific meeting, Atlanta, GA
- 9/27/14 Speaker, "Current Pharmacologic Approaches to the Treatment of Neonatal Abstinence Syndrome" at Medical Society of Delaware Symposium, "The Face of Addiction: Across the Ages", Wilmington, DE
- 5/14/15 Speaker, "Changes in Clinical Trials: The PI perspective", ACRP Greater Philadelphia Chapter's annual 2-day meeting, Blue Bell, PA
- 12/8/15 Speaker, "Pharmacologic Management of the Neonatal Abstinence Syndrome". NIDA Webinar Series
- 2/23/16 Speaker, Substance Abuse Treatment Center, University of Pennsylvania, "Pharmacologic Treatment of the Neonatal Abstinence Syndrome"
- 9/12/16 Speaker, "Modeling, simulation and dose selection in NAS", International Neonatal Consortium of the Critical Path Meeting, European Medicines Agency, Canary Warf, London, UK
- 9/19/16 Session Co-Chair, "Award Winning Abstract Selection" American College of Clinical Pharmacology scientific meeting, Bethesda, MD
- 5/7/17 Platform Speaker, "Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome", Pediatric Academic Societies meeting, San Francisco, CA
- 12/12/17 Platform Speaker, "What is new in Neonatal Abstinence Syndrome", at Hot Topics in Neonatology, Washington, DC
- 1/12/18 Panel Speaker, NIDA Neonatal Opioid Withdrawal Syndrome symposium, Rockville, MD
- 6/6/18 NIDA CTN Youth Special Interest Group presentation, Webinar
- 6/27/18 Speaker, "Clinical Dosing and Pharmacokinetics Considerations for Neonatal Abstinence Disease Treatment", HESI joint session at The Teratology Society meeting, Clearwater, FL
- 9/27/18 Speaker, "Buprenorphine in Neonatal Abstinence Syndrome", Mid-Atlantic Pharmacology Society of ASPET, Philadelphia, PA
- 10/10/18 Speaker, "New Evidence in Managing the Opioid-Exposed Neonate" Advances in Neonatal-Perinatal Medicine, Children's Hospital of Philadelphia

- 10/19/18 Speaker, "Pharmacological treatment of NAS: New Developments, How Do They Compare to Established Standards" Cleveland Clinic 3rd State-of-the-Art Reviews in Neonatal and Perinatal Medicine, Cleveland, OH
- 10/25/18 Speaker, "Human Subjects Protection in Early Phase Clinical Research" Pennsylvania Drug Discovery Institute at The Pennsylvania Biotechnology Institute of Bucks County
- 4/25/19 Speaker/Facilitator, "NAS Pharmacologic Treatment Protocols", Pennsylvania Perinatal Quality Collaborative meeting, Harrisburg, PA
- 5/2/19 A Clinical Trialist's Perspective on Harmonization of Trial Elements. The International Neonatal Consortium of the Critical Path Initiative, Bethesda, MD
- 7/19/19 Speaker, "Optimizing Pharmacological Treatment for NAS", Neonatal Grand Rounds, Cincinnati Children's Hospital
- 9/12/19 Speaker, "Novel Treatments for Neonatal Abstinence", Neonatal Grand Rounds, Tufts Medical Center, Boston, MA
- 1/31/20 Speaker, "Pharmacologic Strategies in the Neonatal Abstinence Syndrome", A Day with the Newborn, St. Christopher's Hospital for Children, Philadelphia, PA
- 8/22/20 Speaker, "State of the Science of Buprenorphine in Nows", NICHD seminar: Toward the Use of Buprenorphine in Infants: Scientific and Practical Considerations
- 7/9/2021 Speaker, "Dose Optimization of Buprenorphine for Neonatal Opioid Withdrawal Syndrome", UNTHSC College of Pharmacy Pharmacometrics Symposium